Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

BRM
8608
BRUGM
89476
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
Chapter 53, Part VI, pp. 961-971, 2007
Bromide, Blood
Clinical Information: Bromides are ingested principally as sedatives. They are used outside the
United States to treat grand mal and focal epilepsy. Bromide shares the same volume of distribution as
chloride, competes with chloride for renal excretion, and has a blood half-life of 12 to 15 days. Signs of
acute toxicity include nausea, vomiting, and diarrhea. Manifestations of chronic toxicity can include
lethargy, fatigue, irritability, loss of appetite, tachypnea, skin pigmentation, hallucinations, ataxia, and
coma.
Useful For: Assessing possible toxicity
Interpretation: Therapeutic concentration: 1,000-2,000 mcg/mL Toxic concentration: > or =3,000
mcg/mL
Reference Values:
Therapeutic concentration: 1,000-2,000 mcg/mL
Toxic concentration: > or =3,000 mcg/mL
NIH Unit
Therapeutic concentration: 12.5-25.0 mmol/L
Toxic concentration: >27.5 mmol/L
Clinical References: Bowers GN Jr, Onoroski M: Hyperchloremia and the incidence of bromism in
1990 (editorial). Clin Chem 1990;36:1399-1403
Brucella Antibody Screen, IgG & IgM, Serum
Clinical Information: Worldwide, brucellosis remains a major disease in humans and domesticated
animals. Brucella infects goats (Brucella melitensis), cattle (Brucella abortus), swine (Brucella suis), and
dogs (Brucella canis).(1) The disease has a limited geographic distribution. Few cases occur in the United
States, with the bulk occurring in the Mediterranean region, Western Asia, and parts of Latin America and
Africa. Three species of Brucella commonly cause disease in humans: Brucella melitensis, Brucella suis,
and Brucella abortus. The acute disease often presents with fever, chills, and malaise; the chronic form
also causes abscesses in bone, brain, spleen, liver, and kidney.
Useful For: Evaluating patients with suspected brucellosis
Interpretation: In the acute stage of the disease there is an initial production of IgM antibodies,
followed closely by production of IgG antibodies. IgG-class antibodies may decline after treatment;
however, high levels of circulating IgG-class antibodies may be found without any active disease. Chronic
brucellosis shows a predominance of IgG-class antibodies with little or no detectable IgM. Rising levels
of specific antibody in paired sera can be regarded as serological evidence of recent infection. The
presence of specific IgM in a single specimen may also indicate a recent infection, although IgM-class
antibodies may persist for months following acute disease. The Centers for Disease Control and
Prevention (CDC) recommends that specimens testing positive for IgG or IgM by enzyme-linked
immunosorbant assay (ELISA) be confirmed by a Brucella-specific agglutination method.(2) The
CDC/Council of State and Territorial Epidemiologists case definition for human brucellosis states that the
laboratory criteria for diagnosis includes 1) Isolation of Brucella species from a clinical specimen, 2)
Four-fold or greater rise in Brucella agglutination titer between acute- and convalescent-phase serum
specimens obtained >2 weeks apart and studied at the same laboratory, or 3) Demonstration by
immunofluorescence of Brucella species in a clinical specimen. Positive results by ELISA that are not
confirmed by Brucella-specific agglutination may represent false-positive screening results. If clinically
indicated, a new specimen should be tested after 7 to 14 days. If results of ELISA are negative and a
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 298